Can anyone tell me the difference between our in-house HER-Haxx and our newly acquired B-Vaxx?
From the limited reading material, I feel they kind of over-lap each other.
Is it a case of we have to acquire the entirety of the competition's portfolio, rather than we need B-Vaxx?
If B-Vaxx doesn't perform as well as our HER-Vaxx in Phase II trials, I can see management subtlely putting it in the bottom draw. But at the same time, it may also act as a level of security for the company if HER-Vaxx fails.
Essentially, multiple shots at the one receptor target.
Management certainly have their strategy well thought out.
Can anyone tell me the difference between our in-house HER-Haxx...
-
- There are more pages in this discussion • 131 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $386.7M | |||
| Open | High | Low | Value | Volume |
| 3.9¢ | 3.9¢ | 3.7¢ | $388.1K | 10.11M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 146314 | 3.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.9¢ | 2536521 | 6 |
View Market Depth
| Last trade - 16.10pm 02/12/2024 (20 minute delay) ? |
| IMU (ASX) Chart |
